Table 1.
Responses from 49 UK hematologists participating in the survey
| Hematologist response, % | Eltrombopag | Romiplostim |
|---|---|---|
| Criteria used to define “well controlled” ITP for and discontinuation TPO-RA tapering | ||
| Stable platelet count | 58 | 76 |
| Well-controlled symptoms or symptom-free | 25 | 0 |
| Lack of or reduced risk of bleeding | 17 | 24 |
| Reasons for treatment re-initiation | ||
| Platelet count | 100 | 100 |
| Clinical symptoms | 67 | 75 |
| Other | 20 | 0 |
| Type of therapy used at treatment re-initiation | ||
| Eltrombopag | 44 | 28 |
| Romiplostim | 41 | 39 |
| Other pharmacologic treatment | 11 | 7 |
| Surgery | 6 | 4 |
| Other nonpharmacologic regimen | 2 | 1 |
ITP, immune thrombocytopenia; TPO-RA, thrombopoietin receptor agonist.